FDA Breast Cancer Patient Meeting Likely To Examine Differences Between Early Stage And Metastatic Experiences
This article was originally published in Pharmaceutical Approvals Monthly
In April, FDA’s patient focused drug development initiative will look at one of the most emotionally and politically fraught areas of advocacy: breast cancer. Here’s a look at what the agency is likely to hear.
You may also be interested in...
Agency’s Patient Network Annual Meeting will help explain the drug development process along with agency and patient roles as part of ongoing effort to increase patient involvement.
Public Company Edition: Mergers with special purpose acquisition corporations may be heating up, but in addition to the Surrozen and Tango SPAC deals Recursion and Biomea launched initial public offerings. Also, Organon sells $5.6bn worth of notes to fund spinout from Merck & Co.
Efforts to improve trial diversity predate COVID-19, but the pandemic’s disproportionate effects on minority communities have brought the issue to the forefront.